u/PVReporter

New Phase 2 results for divesiran could matter to people with PV who require frequent phlebotomies.

In the SANRECO trial, 88% of divesiran-treated patients kept hematocrit below 45% without phlebotomy during weeks 18 through 36, compared with 19% on placebo. The every-12-week group also showed an 81.3% response rate.

These are promising topline findings, but divesiran remains investigational. Full data and a larger Phase 3 trial are still needed.

https://pvreporter.com/divesiran-cuts-phlebotomy-need-in-phase-2-pv-trial/

New 2-year SURPASS-ET data: high-risk ET patients who started ropeginterferon earlier had 76.9% progression-free survival at 24 months, compared to 43.1% for those whose treatment was delayed.

https://pvreporter.com/surpass-et-earlier-ropeginterferon-shows-2-year-benefit/

Seven years. Two medications. Five failed doctors.

When I was diagnosed with polycythemia vera in 2009, no one told me remission was possible. The only treatment I was offered, phlebotomy, guaranteed it wouldn't be.

Today my blood counts are normal. The molecular markers driving my PV are undetectable.

I just published the most personal article I've ever written. It covers how I got here, what it cost, the moment at ASH 2015 that changed everything, and what I want every PV patient to know.

This isn't a typical outcome. I won't pretend it is. But most patients are never told deeper responses are even on the table, and they deserve to know.

Read the full story: https://pvreporter.com/polycythemia-vera-molecular-remission/